Four years of persistent depression unresponsive to two SSRIs, one SNRI, and 16 sessions of CBT. Functional but describes life as 'gray.' Sleep disrupted, anhedonia, loss of creative interests. Says: 'I've done everything right — therapy, meds, exercise. Nothing reaches wherever this lives.'
History
No trauma history she identifies. Loving family, stable career. First depressive episode at 24. Meditation retreat at 30 was the only time she felt 'something break through.' Interested in psychedelic-assisted therapy after reading about psilocybin research. Physician supportive.
Clinical note: Psychedelic-assisted therapies are the most rapidly evolving area in clinical practice. Ketamine is legally available off-label; psilocybin has FDA Breakthrough Therapy designation with strong phase 2 data (Davis et al., 2021: d = 1.0+ for depression; Goodwin et al., 2022 in NEJM). The FDA declined to approve MDMA for PTSD in 2024, citing methodological concerns including functional unblinding and expectancy effects. Sofia's case is instructive: her meditation retreat response suggests she may benefit from non-ordinary state work, but the ISTDP and ACT formulations raise the possibility that the depression itself is a defense or a struggle — and that psychedelics might bypass rather than resolve the underlying issue. The clinical question is whether her treatment resistance reflects neurobiological rigidity (favoring pharmacological intervention), defended affect (favoring ISTDP), or existential confrontation (favoring contemplative approaches). These are not just different treatments but different ontologies of depression.
Where Approaches Genuinely Disagree
Is the medicine the treatment or the relationship?
PSIP
The psychedelic experience itself is the primary therapeutic agent — the therapist supports but the medicine does the work.
vs.
Psychoanalysis
Without relational processing, psychedelic insights remain disconnected experiences. Integration IS the therapy.